Netherlands· NL-427e90e53e31

Enurev Breezhaler 44 microgram inhalatiepoeder in harde capsules

A glycopyrronium bromid product containing glycopyrroniumbromide, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.

ATC R03BB06

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about glycopyrroniumbromideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Glycopyrronium bromid is registered in 12 of 19 countries.

Countries holding a registration under ATC R03BB06 (glycopyrronium bromid), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search glycopyrronium bromid products by name

Glycopyrronium bromid · ATC R03BB06

12 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of glycopyrronium bromid costs, country by country.

Normalised to the WHO defined daily dose (44 mcg), the median price runs from $0.95 in Italy to $1.46 in Switzerland — a ×1.5 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Glycopyrronium bromid · price per daily dose (44 mcg)

USD · FX 28 Sept 2026

CH Switzerland$1.46
IT Italy$0.95

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: GLYCOPYRRONIUMBROMIDE
Manufacturer: Novartis Europharm Limited
Country: Netherlands (NL)
ATC code: R03BB06
ATC class: Glycopyrronium bromid
Defined daily dose: 44 mcg, Inhal
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/12/789

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

213 interactions on record for glycopyrronium bromid.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check glycopyrronium bromid against other medicines How interaction checks work

Glycopyrronium bromid · interactions on record

213 records

6 severe
190 moderate
17 minor

Most severe, free to view

Potassium chlorideA12BA01severe
Potassium citrateA12BA02severe
Potassium chlorideB05XA01severe
TopiramatN02CX12severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glycopyrronium bromid in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glycopyrronium bromid products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

Austria · Rybrila
Germany · Rybrila
Spain · Axhidrox
Sweden · Glycopyrronium Cantabria

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/ff9b1fe2-169c-45c0-b558-364bbaae1717
GET /v1/drugs/ff9b1fe2-169c-45c0-b558-364bbaae1717?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Inhalatiepoeder in harde capsule",
  "route": "Inhalatie",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/enurev-breezhaler-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Glycopyrronium bromide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp111289",
  "excipients": [
    "AMMONIA (E 527)",
    "CARRAGEENAN (E 407)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE ZWART (E 172)",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMHYDROXIDE (E 525)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "ZONNEGEEL FCF (E 110)",
    "ZWARTE INKT"
  ],
  "substances": [
    "GLYCOPYRRONIUMBROMIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2012/09/28",
  "procedure_number": "EMEA/H/C/002691",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/12/789",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about glycopyrronium bromid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console